ArticleFrontiers in microbiology2016
The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum.
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Safe and effective control of Mycoplasma gallisepticum: pharmacokinetic and residue profiling of doxycycline combined with quercetin nanomicelles.Veterinary research communications · 2026Article
- Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum.Poultry science · 2026Article
- Pharmacokinetics of Doxycycline in Alpacas After Intravenous and Subcutaneous Administration.Antibiotics (Basel, Switzerland) · 2025Article
- Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.BMC veterinary research · 2024Article
- Pharmacokinetic behaviour and pharmacokinetic-pharmacodynamic integration of doxycycline in rainbow trout (Oncorhynchus mykiss) after intravascular, intramuscular and oral administrations.Veterinary medicine and science · 2024Article
- Evaluation of the mutant selection window of danofloxacin againstFrontiers in veterinary science · 2023Article
- Population Pharmacokinetics of Doxycycline, Administered Alone or with N-Acetylcysteine, in Chickens with ExperimentalPharmaceutics · 2022Article
- The Monitoring ofAntibiotics (Basel, Switzerland) · 2022Article
- Rational Use of Danofloxacin for Treatment ofAntibiotics (Basel, Switzerland) · 2022Article
- Pharmacokinetic and Pharmacodynamic integration of tilmicosin againstFrontiers in veterinary science · 2022Article
- Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models.Frontiers in veterinary science · 2022Review
- Doxycycline pharmacokinetics in geese.Journal of veterinary pharmacology and therapeutics · 2021Article
- Pharmacokinetic/Pharmacodynamic Modeling of Spiramycin againstPathogens (Basel, Switzerland) · 2021Article
- PK/PD Analysis of Marbofloxacin by Monte Carlo Simulation againstAnimals : an open access journal from MDPI · 2021Article
- Determination of Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Parameters of Doxycycline againstAntibiotics (Basel, Switzerland) · 2021Article
- Kill Rate and Evaluation ofFrontiers in veterinary science · 2021Article
- The PK/PD Integration and Resistance of Tilmicosin againstPathogens (Basel, Switzerland) · 2020Article
- Article
- Tissue Residues and Pharmacokinetic/Pharmacodynamic Modeling of Tiamulin AgainstFrontiers in veterinary science · 2020Article
- The Pharmacokinetics of Doxycycline in Channel Catfish (Frontiers in veterinary science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma gallisepticum is one of the most important pathogens that cause chronic respiratory disease in chicken. This study investigated the antibacterial activity of doxycycline against M. gallisepticum strain S6. In static time-killing studies with constant antibiotic concentrations [0-64 minimum inhibitory concentration (MIC)], M. gallisepticum colonies were quantified and kill rates were calculated to estimate the drug effect. The half-life of doxycycline in chicken was 6.51 ± 0.63 h. An in vitro dynamic model (the drug concentrations are fluctuant) was also established and two half-lives of 6.51 and 12 h were simulated. The samples were collected for drug concentration determination and viable counting of M. gallisepticum. In static time-killing studies, doxycycline produced a maximum antimycoplasmal effect of 5.62log10 (CFU/mL) reduction and the maximum kill rate was 0.11 h(-1). In the in vitro dynamic model, doxycycline had a mycoplasmacidal activity in the two regimens, and the maximum antimycoplasmal effects were 4.1 and 4.75log10 (CFU/mL) reduction, respectively. Furthermore, the cumulative percentage of time over a 48-h period that the drug concentration exceeds the MIC (%T > MIC) was the pharmacokinetic-pharmacodynamic index that best correlated with antimicrobial efficacy (R (2) = 0.986, compared with 0.897 for the peak level divided by the MIC and 0.953 for the area under the concentration-time curve over 48 h divided by the MIC). The estimated %T > MIC values for 0log10 (CFU/mL) reduction, 2log10 (CFU/mL) reduction and 3log10 (CFU/mL) reduction were 32.48, 45.68, and 54.36%, respectively, during 48 h treatment period of doxycycline. In conclusion, doxycycline shows excellent effectiveness and time-dependent characteristics against M. gallisepticum strain S6 in vitro. Additionally, these results will guide optimal dosing strategies of doxycycline in M. gallisepticum infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.